Amphastar Pharmaceuticals
AMPH
136 hedge funds and large institutions have $491M invested in Amphastar Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 55 increasing their positions, 38 reducing their positions, and 15 closing their positions.
45% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 38
13% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 15
1% more funds holding
Funds holding: 135 → 136 (+1)
1.88% less ownership
Funds ownership: 57.01% → 55.13% (-1.9%)
17% less capital invested
Capital invested by funds: $591M → $491M (-$100M)
82% less call options, than puts
Call options by funds: $203K | Put options by funds: $1.11M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.87M |
| 2 |
Two Sigma Advisers
New York
|
+$3.16M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.82M |
| 4 |
Two Sigma Investments
New York
|
+$2.73M |
| 5 |
Goldman Sachs
New York
|
+$2.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VOYA Investment Management
Atlanta,
Georgia
|
-$8.38M |
| 2 |
Nordea Investment Management
Stockholm,
Sweden
|
-$5.28M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$2.97M |
| 4 |
Renaissance Technologies
New York
|
-$2.68M |
| 5 |
Bessemer Group
Woodbridge,
New Jersey
|
-$2.51M |
AMPH Hedge Fund Activity: Q3 2020 in Review
136 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q3 2020, worth a combined $491M — down 17% from $591M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new AMPH positions and 15 closed out — a net gain of 2 holders — while 55 added to existing stakes and 38 trimmed.
The largest buyer was BlackRock, adding an estimated $5.87M. The largest seller was VOYA Investment Management, cutting an estimated $8.38M.
- 136 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q3 2020, up from 135 in Q2 2020.
- Funds reported $491M of Amphastar Pharmaceuticals stock for Q3 2020, down 17% quarter-over-quarter.
- 17 funds opened new Amphastar Pharmaceuticals positions in Q3 2020 and 15 closed out, a net change of +2 holders.
- The largest Amphastar Pharmaceuticals buyer in Q3 2020 was BlackRock, an estimated $5.87M added.
- The largest Amphastar Pharmaceuticals seller in Q3 2020 was VOYA Investment Management, an estimated $8.38M sold.
Based on aggregated 13F filings for Q3 2020.